Newborn Screening - Global Strategic Business Report

The global market for Newborn Screening was valued at US$873.2 Million in 2025 and is projected to reach US$1.5 Billion by 2032, growing at a CAGR of 7.5% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Newborn Screening Market - Key Trends & Drivers Summarized

What Is Newborn Screening and Why Is It Essential?

Newborn screening is a vital public health program that tests infants for certain genetic, metabolic, and developmental disorders shortly after birth. These screenings are essential for detecting conditions that, if left untreated, can lead to severe health problems, including developmental delays, physical disabilities, and even death. Early detection through newborn screening allows for timely interventions, such as medications, dietary changes, or surgeries, which can prevent long-term complications and improve the child's quality of life.

Newborn screening programs typically include tests for a variety of conditions, such as phenylketonuria (PKU), congenital hypothyroidism, sickle cell disease, cystic fibrosis, and more. With the continuous advancement in technology, the range of detectable disorders is expanding, making newborn screening an indispensable tool in modern healthcare. By identifying these conditions early, newborn screening programs contribute to reducing infant mortality and improving overall public health outcomes.

How Is the Newborn Screening Market Evolving?

The newborn screening market is evolving rapidly, driven by technological advancements and the expansion of screening panels. One of the key trends shaping the market is the increasing use of tandem mass spectrometry (MS/MS), a technology that allows for the detection of multiple metabolic disorders from a single blood sample. This technology has revolutionized newborn screening by enabling faster, more accurate, and comprehensive testing. Additionally, genetic screening techniques, including next-generation sequencing (NGS), are being integrated into newborn screening programs, allowing for the detection of a broader range of genetic conditions, including rare diseases.

Another significant trend is the shift towards point-of-care testing (POCT) for newborn screening. POCT devices are portable and enable immediate testing and results at the bedside, reducing the time it takes to begin treatment for diagnosed conditions. The expansion of digital healthcare platforms is also playing a role in the evolution of the market by streamlining data collection, analysis, and reporting processes, leading to more efficient newborn screening workflows. This evolution is allowing more infants to be screened faster, particularly in regions where access to healthcare infrastructure may be limited.

Which Conditions Are Driving the Demand for Newborn Screening?

Several conditions are driving the demand for newborn screening, with metabolic disorders such as phenylketonuria (PKU) and congenital hypothyroidism being among the most commonly screened. These conditions can cause serious developmental issues if not detected early, but with appropriate interventions, their impacts can be significantly mitigated. Genetic disorders, such as cystic fibrosis and sickle cell disease, are also major drivers of screening demand, as early treatment can prevent severe complications and improve long-term health outcomes.

Additionally, lysosomal storage disorders (LSDs), which are a group of rare genetic conditions, are increasingly being included in newborn screening panels. As diagnostic technologies improve, more rare diseases are being detected, leading to early treatments that can improve the prognosis for affected children. The rise of inherited metabolic disorders, which require early dietary interventions, is also contributing to the growing demand for newborn screening programs across the globe.

What Are the Key Growth Drivers in the Newborn Screening Market?

The growth in the newborn screening market is driven by several factors, including the increasing prevalence of genetic and metabolic disorders, which necessitate early diagnosis and intervention. Government mandates and initiatives focused on expanding newborn screening programs are a key driver, as they ensure that a growing number of conditions are included in routine testing. Technological advancements, particularly in mass spectrometry and genetic sequencing, are also propelling market growth by enabling more comprehensive and accurate screening.

Another important factor is the rising awareness among healthcare providers and parents about the importance of early detection in preventing long-term health complications. As healthcare infrastructure improves, especially in developing regions, access to newborn screening is expanding, contributing to market growth. Additionally, collaborations between public health organizations and private companies are increasing, leading to more widespread adoption of advanced screening technologies and better patient outcomes.

Report Scope

The report analyzes the Newborn Screening market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Product Type (Consumables, Instruments); Test Type (Dry Blood Spot Tests, Hearing Screening Tests, Critical Congenital Heart Disease (CCHD) Screening Tests); Technology (Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry, Other Technologies).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Consumables segment, which is expected to reach US$1 Billion by 2032 with a CAGR of a 7.9%. The Instruments segment is also set to grow at 6.7% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $237.9 Million in 2025, and China, forecasted to grow at an impressive 11.5% CAGR to reach $314.4 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Newborn Screening Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Newborn Screening Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Newborn Screening Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Agilent Technologies, Inc., Baebies Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, GE Healthcare Technologies, Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Newborn Screening market report include:

• Agilent Technologies, Inc.
• Baebies Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• GE Healthcare Technologies, Inc.
• Medtronic PLC
• Natus Medical, Inc.
• Qiagen N.V.
• Revvity, Inc.
• Trivitron Healthcare
• Waters Corporation

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.